Theratechnologies Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TH.TO research report →
Companywww.theratech.com
Theratechnologies Inc. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients.
- CEO
- Paul Lévesque
- IPO
- 1996
- Employees
- 103
- HQ
- Montreal, QC, CA
Price Chart
Valuation
- Market Cap
- $205.53M
- P/E
- -13.08
- P/S
- 2.41
- P/B
- -5.74
- EV/EBITDA
- -40.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 76.89%
- Op Margin
- 1.47%
- Net Margin
- -19.83%
- ROE
- 47.31%
- ROIC
- 5.79%
Growth & Income
- Revenue
- $85.87M · 5.02%
- Net Income
- $-8,306,000 · 65.33%
- EPS
- $-0.17 · 48.48%
- Op Income
- $8.17M
- FCF YoY
- 111.73%
Performance & Tape
- 52W High
- $4.73
- 52W Low
- $1.59
- 50D MA
- $4.46
- 200D MA
- $3.32
- Beta
- 0.81
- Avg Volume
- 52.71K
Get TickerSpark's AI analysis on TH.TO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our TH.TO Coverage
We haven't published any research on TH.TO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TH.TO Report →